Jay Galeota, Kallyope CEO
February 15, 2022 08:00 AM EST
Financing

In putting to­geth­er a $236M Se­ries D, one biotech spurns Nas­daq and sig­nals the dim­ming al­lure of IPOs

Max Gelman

Senior Editor

As the biotech IPO mar­ket con­tin­ues to floun­der af­ter a record pan­dem­ic run, the ques­tion must be asked: Are com­pa­nies be­com­ing so IPO-averse that they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times